A Phase 3 interventional study of R89674 0.025% ophthalmic solution in Allergic Conjunctivitis, sponsored by Vistakon Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2011-09-27.
Sponsored by Vistakon Pharmaceuticals · Phase 3, Interventional, and Treatment
The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis
361 studies on the registry are indexed under Conjunctivitis; 17 are open to participants now.
This study's enrollment of 365 is above the median of 100 across 299 interventional studies indexed under Conjunctivitis.
Browse Conjunctivitis studies →Vistakon Pharmaceuticals is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Ocular itching and redness scores at defined timepoints
QOL, severity of chemosis & redness, ocular itching and redness scores at defined timepoints
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vistakon Pharmaceuticals